ImmuneID, Inc., a Cambridge, Mass.-based precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, raised $17M in funding.
The round was led by Longwood Fund, with participation from Arch Venture Partners, Pitango HealthTech, In-Q-Tel, Xfund, and others.
The company plans to use this funding to develop therapeutic programs in areas including severe allergy, autoimmunity, oncology, and infectious disease.
Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), and and led by Lea Hachigian, Ph.D., founding CEO, ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
The company’s Scientific Advisory Board includes co-founder Stephen Elledge, Ph.D.; co-founder H. Benjamin Larman, Ph.D., Assistant Professor Pathology, Johns Hopkins; co-founder Tomasz Kula, Ph.D., Harvard Society of Fellows, Harvard University; and Michael Mina, M.D., Ph.D., Assistant Professor, Epidemiology, Harvard T.H. Chan School of Public Health.